Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

Salbutamol clinical trials

Also listed in trial records as Ventolin
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our Canada, China, Poland and Turkey registers that name Salbutamol as an intervention. Synced 13 Nov 2026
5Current trials
2Recruiting now
4Lead sponsors
4Country registers
At a glance

Salbutamol is named as an intervention in 5 current clinical trials in our Canada, China, Poland and Turkey registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is University of British Columbia (2). The most-studied condition is Paroxysmal Atrial Fibrillation. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.

Salbutamol also has an approved-drug profile on this site (FDA label data): Ventolin (Salbutamol) →

Where Salbutamol is approved

All regulators →

Of the three regulators tracked here, the first to approve Salbutamol was Canada, on 25 Jan 1994.

USUnited States (FDA)
No FDA approval of a single-substance product in Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
No centralised EU authorisation (it may be authorised nationally)
First centralised authorisation
CACanada (Health Canada)
25 Jan 1994
Pms-salbutamol
Notice of Compliance 5533
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Salbutamol

All medicines →
ENNHS England
£49.4m
15,268,654 items dispensed, Sep 2025 to Aug 2026
-18% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
No single-ingredient product reimbursed by Medicaid in 2025
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Salbutamol works

All drug targets →
  • Beta-2 adrenergic receptor agonist Agonist
    Target: ADRB2 adrenoceptor beta 2
    ✓ In ChEMBL and the Guide to Pharmacology
Diseases it has been tested for in clinical trials, by furthest phase
  • Abdominal painPhase 3
  • Riley-Day syndromePhase 3
  • WheezingPhase 3
  • Persistent fetal circulation syndromePhase 3
  • Pulmonary arterial hypertensionPhase 3
  • Pulmonary hypertensionPhase 3
  • Pulmonary hypertension, neonatalPhase 3
  • Congestive heart failurePhase 2/3
  • Myasthenia gravisPhase 2/3
  • Pulmonary edemaPhase 2/3
26 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL714, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 558, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Salbutamol

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Salbutamol

ChEMBL
CHEMBL714
DrugBank
DB01001
PubChem CID
2083
CAS number
18559-94-9
FDA UNII
QF8SVZ843E
Wikidata
Q93346928

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

  • Recruiting240%
  • Not yet open120%
  • Active, closed240%

Trials by phase

  • Not applicable480%
  • Phase 3120%
01

Clinical trials of Salbutamol

5 trials
StudyPhaseStatusLead sponsorRegisters
Effects of Salbutamol in Athletes and Implications for Screening and Sports
NCT07037511 · ClinicalTrials.gov ↗ · Asthma, Healthy, Effect of Drug
Not applicable Recruiting University of British Columbia Canada
Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fibrillation
NCT07877519 · ClinicalTrials.gov ↗ · Paroxysmal Atrial Fibrillation
Not applicable Recruiting China National Center for Cardiovascular Diseases China
Effect of Intraoperative Salbutamol Administration on Mechanical Power and Respiratory Mechanics in Obese Patients Undergoing Laparoscopic Bariatric Surgery
NCT07378605 · ClinicalTrials.gov ↗ · Bariatric Surgery
Not applicable Not yet open Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital Turkey
the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)
NCT05527704 · ClinicalTrials.gov ↗ · TTN, Respiratory Failure, PPHN
Phase 3 Active, closed Medical University of Warsaw Poland
CF Bronchodilation
NCT03522831 · ClinicalTrials.gov ↗ · Lung Diseases, Cystic Fibrosis
Not applicable Active, closed University of British Columbia Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Salbutamol in the EU trials register (CTIS)

4 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Salbutamol. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

StudyPhaseStatusSponsorCountries
A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy, Safety, and Tolerability of AGMB-447 in Participants with Idiopathic Pulmonary Fibrosis
2026-526404-71-00 · CTIS ↗ · Respiratory Tract Diseases
Phase 2 Authorised Agomab Spain S.L.U Poland, France, Belgium + 5 more
A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients with Severe Asthma not Adequately Controlled with Medium to High Dose ICS/LABA Therapy (PANAIRAMA)
2023-509125-41-00 · Respiratory Tract Diseases
Phase 2 Ongoing Kinaset Therapeutics Inc Czechia, Bulgaria, Romania + 4 more
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00 · CTIS ↗ · Respiratory Tract Diseases
Phase 3 Ongoing Novartis Pharma AG Poland, France, Slovakia + 4 more
A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma
2025-521230-29-00 · CTIS ↗ · Immune System Diseases
Phase 3 Ongoing LETI Pharma S.L.U Spain, Portugal
03

Salbutamol across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

13 single-substance products containing Salbutamol on the HPRA medicines list.

All 13 Irish products →

Supply shortages

  • Salbutamol inhalation productsEU (EMA) · Shortage resolved · first published 5 Jun 2024
  • Bronchospray AutohalerGermany (BfArM) · Other reason · 16 Jan 2026 to 1 Feb 2027
  • Cyclocaps Salbutamol 400 µgGermany (BfArM) · Other reason · 1 Aug 2025 to 31 Dec 2026
04

Conditions studied with Salbutamol

10 conditions
Paroxysmal Atrial Fibrillation1TTN1Respiratory Failure1PPHN1Bariatric Surgery1Asthma1Healthy1Effect of Drug1Lung Diseases1Cystic Fibrosis1
05

Sponsors

lead sponsor per trial
Lead sponsorTrials
University of British Columbia2
China National Center for Cardiovascular Diseases1
Medical University of Warsaw1
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital1
06

By country register

RegisterTrialsRecruiting
Clinical trials in Canada21
Clinical trials in China11
Clinical trials in Poland10
Clinical trials in Turkey10
EU register (CTIS)4—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

07

Related compounds

08

Questions about Salbutamol trials

How many clinical trials are testing Salbutamol?

5 current trials in our Canada, China, Poland and Turkey registers name Salbutamol as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.

Are Salbutamol trials recruiting patients?

Yes. 2 of the 5 trials are recruiting: 1 with sites in Canada and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Salbutamol clinical trials?

University of British Columbia (2), China National Center for Cardiovascular Diseases (1), Medical University of Warsaw (1) and Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (1). The number in brackets is how many trials each organisation leads.

Is Salbutamol licensed in Ireland?

Yes. The HPRA medicines list includes 13 single-substance products containing Salbutamol, for example Salamol CFC-Free Inhaler 100 micrograms pressurised inhalation, suspension (Norton Waterford). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Salbutamol shortage?

The registers we track list 3 entries for Salbutamol: Salbutamol inhalation products (EU: shortage resolved); 2 German notices. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Salbutamol works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Salbutamol works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Salbutamol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.